TLSI
TriSalus Life Sciences, Inc.
NASDAQ · Healthcare · Medical - Devices · US
$3.53
−2.75%Sep 22, 2026, 20:15 UTC
TriSalus Life Sciences received U.S. FDA 510(k) clearance for its TriNav Advance device, expanding its Pressure-Enabled Drug Delivery portfolio for liver embolization.
Source:Aug 7, 2026, 05:20 UTC
TriSalus reported a significant revenue miss and lowered its guidance during Q2 2026, citing a Salesforce reorganization and delayed FDA review of its next-generation device.
Source:Aug 6, 2026, 20:05 UTC
TriSalus Life Sciences announced its financial results for the quarter ended June 30, 2026, reporting year-over-year and sequential growth.